Evotec Provides 2025 Revenue Guidance

MT Newswires Live
04-17

Evotec (EVO) said Thursday it expects 2025 revenue of 840 million euros to 880 million euros ($953.9 million to $999.3 million).

Four analysts polled by FactSet expect 851.4 million euros.

The AI-powered medical data collation firm said it expects a 2024 to 2028 compound annual growth rate of 8% to 12%.

Furthermore, the company said tariffs and potential US government funding cuts are expected to have a "limited impact" on its business. It is also planning to simplify its business model and reduce its asset portfolio by around 30%.

Additionally, Evotec plans to use automation and cost-lowering initiatives to produce around 50 million euros in gross savings by 2028 on top of a priority reset that is expected to deliver 40 million euros a year in savings.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10